PDF(Pubmed)
Abstract：
Glioma is the most common type of primary brain tumour which accounts for about 30% of all brain and central nervous system tumours, and approximately 70% of adult malignant brain tumours. Numerous studies have been performed to assess the relationship between ERCC2 rs13181 polymorphism and the risk of glioma development, yet these findings of these studies are often inconsistent and contradictory. Therefore, the aim of this study is to conduct a systematic review and meta-analysis to assess the role of ERCC2 rs13181 in glioma developing. In this work, we have conducted a systematic review and meta-analysis. In order to collect the results of relevant studies on the association of ERCC2 rs13181 gene polymorphism with glioma, we initially searched the Scopus, Embase, Web of Science (WoS), PubMed, and ScienceDirect databases, without a lower time limit, and until June 2020. In order to analyse the eligible studies, the random effects model was used and the heterogeneity of the studies was investigated with the I 2 index. Data analysis was performed within the Comprehensive Meta-Analysis software (version 2). The total number of studies that focused on patients with glioma was 10. The odds ratio of GG vs TT genotype in patients with glioma based on meta-analysis was 1.08 (0.85-1.37: 95% confidence interval), which indicates the increasing effect of GG vs TT genotype by 0.08. The odds ratio of GG + TG vs TT genotype in patients with glioma was 1.22 (1.38-1.7: 95% confidence interval) based on meta-analysis, which indicates the increasing effect of GG + TG vs TT genotype as 0.22. The odds ratio of TG vs TT genotype in patients with glioma was 1.2 (0.38-1.4: 95% confidence interval), which shows the increasing effect of TG vs TT genotype by 0.2. The odds ratio of G vs T genotype in patients with glioma based on the meta-analysis was 1.15 (1.26-1.4: 95% confidence interval), which indicates the increasing effect of G vs T genotype by 0.15. The odds ratio of GG vs TG + TT genotype in patients with glioma based on meta-analysis was 1.22 (1.33-1.45: 95% confidence interval), which indicates the increasing effect of GG vs TG + TT genotype by 0.22. The results of this systematic review and meta-analysis show that ERCC2 rs13181 polymorphism and its genotypes are an important risk factor for genetic susceptibility to glioma tumour.
摘要：
胶质瘤是最常见的原发性脑肿瘤，约占所有脑和中枢神经系统肿瘤的30％，和大约70%的成人恶性脑肿瘤。已经进行了许多研究来评估ERCC2rs13181多态性与神经胶质瘤发展风险之间的关系。然而，这些研究的结果往往不一致和矛盾。因此,本研究的目的是进行系统评价和荟萃分析,以评估ERCC2rs13181在神经胶质瘤发生中的作用.在这项工作中,我们进行了系统评价和荟萃分析.为了收集ERCC2rs13181基因多态性与胶质瘤的相关性的相关研究结果,我们最初搜索了Scopus，Embase,WebofScience(WoS),PubMed,和ScienceDirect数据库，没有较低的时间限制，直到2020年6月。为了分析符合条件的研究，采用随机效应模型,用I2指数考察研究的异质性.在综合荟萃分析软件（版本2）中进行数据分析。针对神经胶质瘤患者的研究总数为10。基于meta分析的胶质瘤患者GG与TT基因型比值比为1.08(0.85-1.37:95%置信区间),这表明GG对TT基因型的影响增加了0.08。根据荟萃分析，胶质瘤患者GG+TG与TT基因型的比值比为1.22(1.38-1.7:95%置信区间)，这表明GG+TG对TT基因型的增加作用为0.22。脑胶质瘤患者TG与TT基因型比值比为1.2(0.38-1.4:95%置信区间),这表明TG对TT基因型的增加效应为0.2。根据荟萃分析，胶质瘤患者G与T基因型的比值比为1.15（1.26-1.4：95％置信区间），这表明G与T基因型的作用增加0.15。基于meta分析的胶质瘤患者GG与TGTT基因型的比值比为1.22（1.33-1.45：95％置信区间），这表明GG与TG+TT基因型的效应增加了0.22。这项系统评价和荟萃分析的结果表明，ERCC2rs13181多态性及其基因型是胶质瘤肿瘤遗传易感性的重要危险因素。
